Matricelf

Matricelf is redefining personalized regenerative medicine through its groundbreaking platform for autologous 3D tissue engineering. Founded in 2019 by Professor Tal Dvir at Tel Aviv University, the company develops curative, patient-specific therapies aimed at restoring function and independence in patients with severe neurological injuries.

Our journey begins with spinal cord injury (SCI)—a devastating condition with no effective cure and a $40B market annual burden in the U.S. alone. By engineering functional neural implants from a patient’s own cells and tissue, Matricelf offers a one-time treatment that has the potential to transform the standard of care and unlock broader therapeutic applications.